Can Men Use Ozempic for Weight Loss? Evidence & Genetics

Last reviewed: May 25, 2026

Last updated: May 25, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Yes, men can use GLP-1 receptor agonist medications like semaglutide for weight loss, with robust clinical evidence supporting efficacy in male participants. The STEP trials included roughly 40% men and demonstrated meaningful weight reduction across genders, though individual responses varied significantly based on baseline metabolic factors.

For men exploring weight loss medication, understanding your unique metabolic profile—including genetic factors that influence GLP-1 receptor function and glucose metabolism—can help guide more personalized treatment decisions with your provider. PlexusDx focuses on precision wellness by helping men evaluate how their biology may respond to different GLP-1 formulations and dosing approaches.

Clinical Evidence for GLP-1 Weight Loss in Men

The STEP 1 trial, which established semaglutide's weight loss efficacy, enrolled approximately 1,300 adults with an obesity diagnosis or weight-related condition. Male participants (n≈500) achieved average weight reductions of 10–15% at therapeutic doses, comparable to female participants, though individual variation was substantial.

Men in the trial reported similar tolerability and dropout rates compared to women, challenging assumptions about gender-specific differences in GLP-1 response. However, male participants with baseline metabolic dysfunction—such as elevated fasting glucose or insulin resistance—showed variable weight loss trajectories, suggesting baseline metabolic state influences outcomes.

How Metabolic Genetics May Influence Male GLP-1 Response

GLP-1 receptor agonists work by enhancing insulin secretion and promoting satiety through GLP1R pathway signaling. Genetic variation in the GLP1R gene (e.g., rs6923761) and related metabolic genes (FTO, MC4R) may affect how efficiently a man's body responds to these medications, influencing both weight loss magnitude and side effect profile.

Genetic Factor	Role in GLP-1 Response	Clinical Relevance for Men
GLP1R rs6923761	Influences GLP-1 receptor sensitivity and signal transduction	Variation may correlate with appetite suppression efficacy and individual dose requirements
FTO rs9939609	Associated with obesity predisposition and metabolic rate	Men with certain variants may show slower or faster initial weight loss; baseline BMI context matters
MC4R rs17782313	Regulates melanocortin pathway affecting appetite control	Polymorphisms may influence satiety response and long-term weight maintenance patterns
GIPR rs1800437	Affects glucose-dependent insulinotropic peptide signaling	May modulate postprandial glucose control and metabolic flexibility on GLP-1 therapy

Formulation Considerations: Injectable vs. Oral GLP-1 Options

Men have two primary administration routes for semaglutide: injectable (compounded or branded versions) and oral formulations. Compounded injectable semaglutide typically offers bioavailability comparable to brand formulations while oral semaglutide requires higher doses due to GI absorption limitations, affecting cost and convenience trade-offs.

For men prioritizing dose flexibility or those with swallowing difficulties, compounded injectable semaglutide provides weekly dosing with predictable pharmacokinetics. Oral semaglutide requires daily dosing on an empty stomach but eliminates injection anxiety for some men, though individual tolerability and adherence differ significantly.

Medical Safety Evaluation and Who Should Consider GLP-1 Therapy

Men considering GLP-1 therapy for weight loss should undergo baseline assessment including BMI ≥27 with weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia) or BMI ≥30 regardless of comorbidity. Contraindications include personal or family history of medullary thyroid carcinoma or MEN 2 syndrome, requiring careful provider screening before initiation.

Common side effects in male participants include nausea, vomiting, diarrhea, and constipation, typically mild-to-moderate and improving over 4–8 weeks. Men with baseline GI conditions, severe renal impairment, or uncontrolled hypertension require modified dosing strategies and closer provider monitoring to ensure safety and efficacy.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context about a man's genetic predispositions in key GLP-1 and metabolic pathways—including GLP1R, FTO, MC4R, and GIPR variants. This information can support a more personalized conversation with a qualified healthcare provider about which GLP-1 formulation and dosing approach aligns with individual biology.

The genetic test reveals predispositions in peptide signaling pathways but does not predict exact medication response or guarantee weight loss outcomes. Test results should always be interpreted with a qualified healthcare provider who can integrate genetic context with clinical history, baseline metabolic markers, and individual health goals.

For men exploring compounded GLP-1 options—such as compounded semaglutide injection or oral tirzepatide—understanding genetic predispositions in appetite regulation and glucose metabolism may help guide informed decisions about starting dose, titration pace, and formulation choice in partnership with a prescribing provider.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What did the STEP 1 trial show about weight loss in male participants compared with female participants?

The post reports that male participants in STEP 1 achieved average weight reductions of 10 to 15% at therapeutic levels, comparable to female participants, with substantial individual variation. It adds that men reported similar tolerability and dropout rates to women, which the article frames as challenging assumptions about gender-specific differences in GLP-1 response.

Which men does the post say showed the most variable weight loss trajectories?

The article says male participants with baseline metabolic dysfunction, such as elevated fasting glucose or insulin resistance, showed variable weight loss trajectories, suggesting baseline metabolic state influences outcomes. It presents this as one reason two men on the same protocol can see very different results, not as a reason to expect the medication to fail.

How does the post frame the trade-off between injectable and oral semaglutide for men?

The post says compounded injectable semaglutide offers bioavailability comparable to brand formulations with weekly administration and predictable pharmacokinetics, while the oral form requires higher amounts because of GI absorption limits and is taken daily on an empty stomach. It frames the choice around cost, convenience, swallowing difficulty, and injection anxiety.

What BMI thresholds does the article describe before GLP-1 therapy is considered for a man?

The post describes baseline assessment using a BMI of 27 or higher paired with a weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia, or a BMI of 30 or higher regardless of comorbidity. It adds that a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome is a contraindication requiring provider screening.

How long does the post say typical side effects last in men before they improve?

The article says common side effects in male participants, including nausea, vomiting, diarrhea, and constipation, are typically mild to moderate and improve over four to eight weeks. It notes that men with baseline GI conditions, severe renal impairment, or uncontrolled hypertension need closer provider monitoring and a modified plan.

Related Reading

• Ozempic For Weight Loss 2
• Average Weight Loss On Ozempic
• Weight Loss Drugs Like Ozempic
• Ozempic Weight Loss Before And After Pictures

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.